An open label, randomized, three period, single-dose, crossover study to determine the bioavailability of 300 mg aliskiren mini-tablets relative to the 300 mg aliskiren market tablet under fasted condition and to evaluate the effect of food on the pharmacokinetics of 300 mg aliskiren minitablets in healthy subjects.
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Aliskiren (Primary)
- Indications Chronic heart failure; Hypertension
- Focus Pharmacokinetics
- Sponsors Novartis
Most Recent Events
- 09 Feb 2010 New trial record